notificationsアラート設定
~
検索条件をクリア

International Journal of Myeloma 11巻 2号

発行元
日本骨髄腫学会
ISSN
ISSN（オンライン）
2187-3143
旧名・別名
抄録集：日本骨髄腫研究会総会 プログラム・抄録集
書籍情報から探す
▼
巻
号
開始頁
第46回日本骨髄腫学会学術集会 温故知新 会長挨拶
坂井晃
第46回日本骨髄腫学会学術集会 会長, 福島県立医科大学医学部 放射線生命科学講座
International Journal of Myeloma 11 (2) 3-3, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.09MB)
PL-1. Study for exploring myeloma-initiating cell using normal B cell-derived induced pluripotent stem cells
Akira Sakai
Radiation Life Sciences, Fukushima Medical University School of Medicine
International Journal of Myeloma 11 (2) 43-43, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.08MB)
SL-1. Immunomodulatory drugs in multiple myeloma : How far have we come?
Teru Hideshima
Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School
International Journal of Myeloma 11 (2) 46-46, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.10MB)
SL-2. Biology of multiple myeloma with t(11 ; 14) (q13 ; q32) based on molecular cytogenetics
Ikuo Miura
Center for Genetic and Chromosomal Analysis, SRL, Inc.
International Journal of Myeloma 11 (2) 47-47, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.23MB)
SY1-1. A new insight into the biology and treatment for bone disease in multiple myeloma
Masahiro Abe
Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School
International Journal of Myeloma 11 (2) 50-50, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
SY1-2. Role of imaging in multiple myeloma patients
Miyuki Takasu
Department of Diagnostic Radiology, Hiroshima City Hiroshima Citizens Hospital
International Journal of Myeloma 11 (2) 51-51, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.27MB)
SY1-3. Anemia in myeloma - diversity and spectrum of pathogenesis -
Akiyoshi Miwa
International Myeloma Center for Advanced Research and Treatment, Tokyo-Kita Medical Center
International Journal of Myeloma 11 (2) 52-52, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
SY1-4. Development of combinatory treatment of Th1-like γδT cells with elotuzumab against osteoclasts as well as myeloma cells
Takeshi Harada1, Yusuke Inoue1, Hirofumi Tenshin2, Asuka Oda1, Ryohei Sumitani1, Masahiro Oura1, Kimiko Sogabe1, Shiro Fujii3, Shingen Nakamura4, Hirokazu Miki5, Kumiko Kagawa3, Masahiro Hiasa2, Jumpei Teramachi6, Masahiro Abe1
1Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, 2Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Biomedical Sciences, 3Department of Hematology, Tokushima University Hospital, 4Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, 5Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 6Department of Oral Function and Anatomy, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
International Journal of Myeloma 11 (2) 53-53, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.07MB)
SY1-5. The prevalence and clinical outcomes of vitamin D deficiency in Japanese multiple myeloma patients : A single-center observational study
Atsushi Isoda1,2, Yuri Miyazawa2, Tetsuya Ishikawa2, Keita Nakayama2, Shuhei Kanaya2, Hirono Iriuchijima2, Akio Saito2, Morio Matsumoto2, Morio Sawamura2
1Department of Hematology, Hoshi Clinic, 2Department of Hematology, Shibukawa medical center
International Journal of Myeloma 11 (2) 54-54, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
SY1-6. The importance of retaining physical functions to prevent SRE in multiple myeloma
Hirokazu Miki1, Shingen Nakamura2, Masafumi Nakamura3, Makiko Mizuguchi3, Ryohei Sumitani3, Masahiro Oura3, Kimiko Sogabe3, Mamiko Takahashi3, Tomoko Maruhashi3, Takeshi Harada3, Shiro Fujii3, Kumiko Kagawa3, Hirofumi Hamano4, Masateru Kondo4, Naoto Okada4, Yoshimi Bando5, Itsuro Endo3, Masahiro Abe3
1Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, 2Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, 3Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 4Department of Pharmacy, Tokushima University Hospital, 5Division of Pathology, Tokushima University Hospital
International Journal of Myeloma 11 (2) 55-55, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
SY2-1. Kidney lesions in multiple myeloma and related diseases
Junichiro James Kazama, Momoko Fujiwara
Division of Nephrology and Hypertension, Fukushima Medical University
International Journal of Myeloma 11 (2) 56-56, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
SY2-2. Gain / amplification of chromosome arm 1q21 and deletion of chromosome 1p in multiple myeloma
Ichiro Hanamura
Division of Hematology, Department of Internal Medicine, Aichi Medical University
International Journal of Myeloma 11 (2) 57-57, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.08MB)
SY2-3. Efficacy and Tolerability of Daratumumab-based regimens in dialysis-dependent Japanese patients with myeloma
Chigusa Kitayama, Shinichi Mizuno
Department of Nephrology, Japan Community Health care Organization Sendai Hospital
International Journal of Myeloma 11 (2) 58-58, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
SY2-4. Multiple myeloma with t(11 ; 14) - associated immature phenotype has lower CD38 expression and higher BCL2 / BCL2L1 ratio
Akihiro Kitadate1,2, Kentaro Narita2, Toshiki Terao2, Sho Ikeda1, Takafumi Tsushima2, Daisuke Miura2, Masami Takeuchi2, Naoto Takahashi1, Kosei Matsue2
1Department of Hematology, Nephrology, and Rheumatology, Akita University, 2Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center
International Journal of Myeloma 11 (2) 59-59, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
SY3-1. Mechanism of amyloid fibril formation in AL amyloidosis: an up-to-date overview
Masayoshi Tasaki1, Mitsuharu Ueda2
1Department of Morphological and Physiological Sciences, Graduate School of Health Sciences, Kumamoto University, 2Department of Neurology, Graduate School of Medical Sciences, Kumamoto University
International Journal of Myeloma 11 (2) 60-60, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
SY3-2. Recent advances in diagnosis and treatment of AL amyloidosis
Nobuhiro Tsukada
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 11 (2) 61-61, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
SY3-3. A retrospective analysis of 21 patients with IgM-related AL amyloidosis in Japan : A Study by the amyloidosis-research-committee
Shin-ichi Fuchida1, Mizuki Ogura2, Tadao Ishida2, Hiroyuki Hata3, Hiroshi Handa4, Nagaaki Katoh5, Chiaki Nakaseko6, Kazutaka Sunami7, Yuta Katayama8, Hironobu Nobata9, Kazukuni Oshiro10, Shinsuke Iida11, Yoshiki Sekijima5, Hironobu Naiki12, Chihiro Shimazaki1
1Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center, 2Department of Hematology, Japanese Red Cross Medical Center, 3Division of Informative Clinical Sciences, Faculty of Medical Sciences, Kumamoto University, 4Department of Hematology, Gunma University Graduate School of Medicine, 5Department of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine, 6Department of Hematology, International University of Health and Welfare School of Medicine, 7Department of Hematology, National Hospital Organization Okayama Medical Center, 8Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Division of Hematology, 9Department of Nephrology and Rheumatology, Aichi Medical University, 10Department of Hematology and Oncology, Okinawa prefectural Nanbu Medical Center, 11Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 12Department of Pathology, University of Fukui
International Journal of Myeloma 11 (2) 62-62, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
SY3-4. Introduction of daratumumab in a patient with AL amyloidosis who developed acute heart failure during VCD
Motoko Kohda, Kyoko Yoshihara, Satoshi Yoshihara, Mami Samori, Nobuto Utsunomiya, Satoshi Higasa
Department of Hematology, Hyogo College of Medicine Hospital
International Journal of Myeloma 11 (2) 63-63, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
JRAL-1. Significance of hypoxia-inducible genes in molecular pathogenesis and therapy resistance of multiple myeloma
Sho Ikeda
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine
International Journal of Myeloma 11 (2) 66-66, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
JRAL-2. Novel immune checkpoint sialic acid-binding Ig-like lectin (Siglec) family molecules in multiple myeloma
Mariko Ishibashi1, Hideto Tamura2, Rimpei Morita1
1Department of Microbiology and Immunology , Nippon Medical School, 2Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center
International Journal of Myeloma 11 (2) 67-67, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
MRGAL-1. The Emerging Roles of Extracellular Vesicles in Multiple Myeloma Progression
Yusuke Yamamoto1, Tomofumi Yamamoto2, Yutaka Hattori2, Takahiro Ochiya3
1Division of Cellular Signaling, National Cancer Center Research Institute, 2Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, 3Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University
International Journal of Myeloma 11 (2) 70-70, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
MRGAL-2. The role of Signal-transducing adaptor protein family in multiple myeloma
Michiko Ichii, Naoki Hosen
Department of Hematology and Oncology, Osaka University Graduate School of Medicine
International Journal of Myeloma 11 (2) 71-71, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
PS-1. Extramedullary diseases originate from hyaluronan-induced homophilic cell-cell interaction of myeloma cells
Jiro Kikuchi1, Nobuyuki Kodama2,3, Masataka Takeshita2,3, Tomoko Hijima2,3, Sho Ikeda4, Takahiro Kobayashi4, Yoshiaki Kuroda5, Norihiro Uchiyama6, Naoki Osada1, Daisuke Koyama1, Bjarne Bogen7, Hiroshi Yasui8, Naoto Takahashi4, Akiyoshi Miwa2,3, Yusuke Furukawa1
1Div. Stem Cell Reg, Cent Mol Med, Jichi Med. Univ., 2Int. Myeloma Cent. Adv. Res. Treat., 3Tokyo-Kita Med. Cent., 4Akita Univ. Grad. Sch. Med., 5Hiroshima-Nishi Med. Cent., 6Jap. Red Cross Soci. Suwa Hosp., 7Univ. Oslo, 8Inst. Med. Sci, Univ. Tokyo
International Journal of Myeloma 11 (2) 74-74, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
PS-2. Critical role of TAK1-mediated upregulation of the endogenous PP2A inhibitor CIP2A in myeloma cell growth and survival
So Shimizu1,2, Jumpei Teramachi3, Takeshi Harada2, Hirofumi Tenshin1,2, Asuka Oda2, Masahiro Hiasa1,2, Masahiro Oura2, Kimiko Sogabe2, Itsuro Endo4, Toshio Matsumoto5, Eiji Tanaka1, Masahiro Abe2
1Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Biomedical Sciences, 2Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, 3Department of Oral Functional and Anatomy, Okayama University, 4Department of Bioregulatory Sciences, Tokushima University Graduate School of Medical Sciences, 5Fujii Memorial Institute of Medical Sciences, Tokushima University
International Journal of Myeloma 11 (2) 75-75, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.07MB)
PS-3. Efficacy of salvage treatment with carfilzomib based rescue chemotherapy followed by HDT / 2nd ASCT in relapsed / refractory multiple myeloma patients
Shinsuke Mizutani1, Saeko Kuwahara-Ota1, Yuka Kawaji-Kanayama1, Ayako Muramatsu1, Haruya Okamoto1, Akio Onishi1, Kentaro Mizuhara1, Yoko Katsuragawa-Taminishi1, Junko Yamaguchi1, Reiko Isa1, Takahiro Fujino1, Daichi Nishiyama1, Yayoi Matsumura-Kimoto1, Taku Tsukamoto1, Yuji Shimura1, Tsutomu Kobayashi1, Kazuho Shimura2, Ryoichi Takahashi3, Hiroto Kaneko2, Junya Kuroda1
1Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 2Department of Hematology, Aiseikai Yamashina Hospital, 3Department of Hematology, Omihachiman Community Medical Center
International Journal of Myeloma 11 (2) 76-76, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
PS-4. SUBCUTANEOUS DARATUMUMAB COMBINATION THERAPIES FOR MULTIPLE MYELOMA : INITIAL RESULTS FOR D-KD AND UPDATED RESULTS FOR D-VMP AND D-RD FROM PLEIADES
Shinsuke Iida1, Philippe Moreau2, Ajai Chari3, Mathias Haenel4, Albert Oriol5, Paula Rodriguez-Otero6, Helen McCarthy7, Kenshi Suzuki8, Vania Hungria9, Anna Sureda Balari10, Lauriane Clement-Filliatre10, Cyrille Hulin10, Hila Magen10, Vladimir Maisnar10, Lionel Karlin10, Ludek Pour10, Cyrille Touzeau10, Shiyi Yang10, Michele Kosh10, Maria Delioukina10, Christoph Heuck10
1Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, 2Hematology, University Hospital Hotel-Dieu, 3Icahn School of Medicine at Mount Sinai, 4Klinikum Chemnitz, 5Institut Catala d'Oncologia i Institut Josep Carreras, Hospital Germans Trias i Pujol, 6Clinica Universidad de Navarra, 7Royal Bournemouth Hospital, 8Department of Hematology, Japanese Red Cross Medical Center, 9Clinica Medica Sao Germano, 10Other
International Journal of Myeloma 11 (2) 77-77, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.00MB)
PS-5. SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB / CYCLOPHOSPHAMIDE / DEXAMETHASONE (D-VCD) IN NEWLY DIAGNOSED AL AMYLOIDOSIS : ASIAN SUBGROUP ANALYSIS FROM ANDROMEDA
Kenshi Suzuki1, Ashutosh D. Wechalekar2, Kihyun Kim3, Chihiro Shimazaki4, Jin Seok Kim5, Takayuki Ikezoe6, Chang-Ki Min7, Fude Zhou8, Shinsuke Iida9, Nagaaki Katoh10, Tomoaki Fujisaki10, Ho-Jin Shin10, NamPhuong Tran10, Xiang Qin10, Sandra Y. Vasey10, Brenda Tromp10, Brendan M. Weiss10, Jessica Vermeulen10, Raymond L. Comenzo10, Efstathios Kastritis10, Jin Lu10
1Department of Hematology, Japanese Red Cross Medical Center, 2University College London and the Royal Free London NHS Foundation Trust, Division of Medicine, Faculty of Medical Sciences, 3Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 4Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center, 5Yonsei University College of Medicine, Severance Hospital, 6Department of Hematology, Fukushima Medical School, 7Seoul St. Mary's Hospital, 8Renal Division, Department of Medicine, Peking University First Hospital, 9Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, 10Other
International Journal of Myeloma 11 (2) 78-78, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(0.99MB)
PS-6. Development of innovative antitumor antibodies armed with Bridging-BiTE to advance anti-myeloma immunotherapy
Tatsuya Konishi1, Toshiki Ochi1,2, Masaki Maruta1, Kazushi Tanimoto1, Takashi Saitou3, Takeshi Imamura3, Masaki Yasukawa2,4, Katsuto Takenaka1
1Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, 2Division of Immune Regulation, Proteo-Science Center, Ehime University, 3Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, 4Ehime Prefectural University of Health Sciences
International Journal of Myeloma 11 (2) 79-79, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.07MB)
PS-7. CARTITUDE-1 : PHASE 1B / 2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED / REFRACTORY MULTIPLE MYELOMA (RRMM)
Deepu Madduri1, Jesus G Berdeja2, Saad Z Usmani3, Andrzej Jakubowiak4, Mounzer Agha5, Adam D Cohen6, A. Keith Stewart7, Parameswaran Hari8, Myo Htut9, Elizabeth O'Donnell10, Nikhil C Munshi11, David Avigan12, Abhinav Deol13, Alexander Lesokhin14, Indrajeet Singh15, Enrique Zudaire15, Tzu-Min Yeh16, Alicia J Allred15, Yunsi Olyslager17, Arnob Banerjee15, Jenna D Goldberg16, Jordan M Schecter16, Carolyn C Jackson16, William Deraedt17, SenHong Zhuang16, Jeffrey Infante16, Dong Geng18, Xiaoling Wu18, Marlene J Carrasco-Alfonso18, Muhammad Akram18, Farah Hossain18, Syed Rizvi18, Frank Fan19, Sundar Jagannath1, Yi Lin20, Thomas Martin21
1Mount Sinai Medical Center, 2Sarah Cannon Research Institute, 3Levine Cancer Institute-Atrium Health, 4University of Chicago, 5UPMC Hillman Cancer Center, 6Abramson Cancer Center, University of Pennsylvania, 7UHN and the Princess Margaret Cancer Centre, 8Medical College of Wisconsin, 9City of Hope Comprehensive Cancer Center, 10Massachusetts General Hospital, Harvard Medical School, 11Dana-Farber Cancer Institute, Harvard Medical School, 12Beth Israel Deaconess Medical Center and Harvard Medical School, 13Karmanos Cancer Institute, Wayne State University, 14Memorial Sloan Kettering Cancer Center, 15Janssen R&D, Spring House, 16Janssen R&D, Raritan, 17Janssen R&D, Beerse, 18Legend Biotech USA, Inc., 19Nanjing Legend Biotechnology Co., Ltd., 20Mayo Clinic, 21UCSF Helen Diller Family Comprehensive Cancer Center
International Journal of Myeloma 11 (2) 80-80, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(0.99MB)
P-1. Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis
Kazuya Ishiguro1,2, Hiroshi Kitajima1, Takeshi Niinuma1, Reo Maruyama3, Tetsuyuki Igarashi2, Hiroshi Nakase4, Hiromu Suzuki1
1Department of Molecular Biology, Sapporo Medical University School of Medicine, 2Department of Hematology, Tenshi Hospital, 3Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, 4Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
International Journal of Myeloma 11 (2) 82-82, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.05MB)
P-2. SORT1 / LAMP2-mediated Exosome Secretion and Cell Adhesion Are Associated with Lenalidomide Resistance in Multiple Myeloma
Tomofumi Yamamoto1,2,3, Jun Nakayama3, Yusuke Yamamoto3, Takahiro Ochiya1, Yutaka Hattori2
1Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, 2Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, 3Division of Cellular Signaling, National Cancer Center Research Institute
International Journal of Myeloma 11 (2) 83-83, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
P-3. KDM5A is a vulnerability of MYC target genes essential to multiple myeloma
Hiroto Ohguchi1, Daisuke Ogiya2, Tingjian Wang3, Berkley Gryder4, Paul Park3, Keiji Kurata2, Deyao Li3, Takeshi Masuda5, Shinjiro Hino6, Shingo Usuki7, Yawara Kawano8, Yu-Tzu Tai2, Nikhil Munshi2, Masao Matsuoka8, Sumio Ohtsuki5, Mitsuyoshi Nakao6, Takashi Minami9, Adam Durbin10, Kenneth Anderson2, Teru Hideshima2, Jun Qi3
1Division of Disease Epigenetics, IRDA, Kumamoto University, 2Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, 3Department of Cancer Biology, Dana-Farber Cancer Institute, 4Genetics Branch, 5Department of Pharmaceutical Microbiolgy, Faculty of Life Sciences, Kumamoto University, 6Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, 7Liaison Laboratory Research Promotion Center, Institute of Molecular Embryology and Genetics, Kumamoto University, 8Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, 9Division of Molecular and Vascular Biology, Institute of Resource Development and Analysis, Kumamoto University, 10Department of Pediatric Oncology, Dana-Farber Cancer Institute
International Journal of Myeloma 11 (2) 84-84, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
P-4. Mechanisms for the resistance to proteasome inhibitors in myeloma cells : the role of PIM2 and Akt kinase activation and NRF2 accumulation
Kimiko Sogabe1, Takeshi Harada1, Shingen Nakamura2, Hirokazu Miki3, Asuka Oda1, Yusuke Inoue1, Rhohei Sumitani1, Masahiro Oura1, Shiro Fujii4, Kumiko Kagawa4, Hirofumi Tenshin5, Masahiro Hiasa5, Jumpei Teramachi6, Masaki Ri7, Shinsuke Iida7, Masahiro Abe1
1Department of Hematology, Endocrinology and Metabolism, University of Tokushima, 2Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, 3Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 4Department of Hematology, Tokushima University Hospital, 5Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Biomedical Sciences, 6Department of Oral Function and Anatomy, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, 7Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences
International Journal of Myeloma 11 (2) 85-85, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.07MB)
P-5. Effects of HDAC inhibitors and IMiDs on CD38 and SLAMF7 expresssion in MM cells
Yusuke Inoue1, Takeshi Harada1, Asuka Oda1, Rhohei Sumitani1, Masahiro Oura1, Kimiko Sogabe1, Shiro Fujii2, Shingen Nakamura3, Hirokazu Miki4, Kumiko Kagawa2, Hirofumi Tenshin5, Masahiro Hiasa5, Jumpei Teramachi6, Masahiro Abe1
1Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Science, 2Department of Hematology, Tokushima University Hospital, 3Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, 4Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 5Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Biomedical Sciences, 6Department of Oral Function and Anatomy, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
International Journal of Myeloma 11 (2) 86-86, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-6. FGFR3 overexpression was not associated with poor survival in t(4 ; 14)+ multiple myeloma patients
Ryosuke Kinoshita1, Mariko Ishibashi2, Hiroshi Handa3, Makoto Sasaki4, Norio Komatsu4, Yoichi Imai5, Shigeki Ito6, Norina Tanaka7, Junji Tanaka7, Atsushi Isoda8, Morio Matsumoto8, Sakae Tanosaki9, Mika Sunakawa1, Toshio Asayama1, Koiti Inokuchi1, Hideto Tamura1,10
1Division of Hematology, Department of Medicine, Nippon Medical School, 2Department of Microbiology and Immunology, Nippon Medical School, 3Department of Hematology, Gunma University, 4Division of Hematology, Juntendo University School of Medicine, 5Department of Hematology and Oncology, IMSUT Hospital, 6Department of Hematology and Oncology, Iwate Medical University, 7Department of Hematology, Tokyo Women's Medical University, 8Department of Hematology, National Hospital Organization Shibukawa Medical Center, 9Department of Hematology, The Fraternity Memorial Hospital, 10Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center
International Journal of Myeloma 11 (2) 87-87, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.07MB)
P-7. The role of CD38 in myeloma cell survival
Yawara Kawano1, Saki Kushima2, Masao Matsuoka1, Hiroyuki Hata2
1Department of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Hospital, 2Division of Informative Clinical Sciences, Faculty of Medical Sciences, Kumamoto University
International Journal of Myeloma 11 (2) 88-88, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-8. Identification of suitable drugs to be combined with venetoclax for the treatment of multiple myeloma
Naoki Osada1, Jiro Kikuchi1, Daisuke Koyama1, Yoshiaki Kuroda2, Hiroshi Yasui3, Yusuke Furukawa1
1Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 2National Hospital Organization, Hiroshima-Nishi Medical Center, 3Institute of Medical Science, University of Tokyo
International Journal of Myeloma 11 (2) 89-89, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
P-9. Retrospective study of peripheral blood stem cell harvest (PBSCH) in patients with multiple myeloma
Masataka Takeshita1,2, Nobuyuki Kodama1,2, Tomoko Hishima1,2, Risen Hirai1, Akira Tanimura1, Kouji Okazaki1, Yuko Okuda1, Daisuke Kudo1, Akiyoshi Miwa1,2
1Department of Hematology, Tokyo-Kita Medical Center, 2International Myeloma Center for Advanced Research and Treatment
International Journal of Myeloma 11 (2) 90-90, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.05MB)
P-10. Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse
Hiroshi Yasui1,2, Masayuki Kobayashi2,3, Kota Sato4, Kanya Kondoh2, Tadao Ishida4, Yuta Kaito5, Hideto Tamura5,6, Hiroshi Handa7, Yutaka Tsukune8, Makoto Sasaki8, Norio Komatsu8, Norina Tanaka9, Junji Tanaka9, Masahiro Kizaki10, Toyotaka Kawamata1, Junya Makiyama1, Kazuaki Yokoyama1, Seiya Imoto2, Arinobu Tojo1,2, Yoichi Imai1
1Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 2The Institute of Medical Science, The University of Tokyo, 3Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, 4Department of Hematology, Japanese Red Cross Medical Center, 5Department of Hematology, Nippon Medical School, 6Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, 7Department of Hematology, Gunma University Graduate School of Medicine, 8Department of Hematology, Juntendo University School of Medicine, 9Department of Hematology, Tokyo Women's Medical University, 10Department of Hematology, Saitama Medical Center, Saitama Medical University
International Journal of Myeloma 11 (2) 91-91, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
P-11. Use of CD319 in detection of myeloma cells in daratumumab era
Yoshiaki Kuroda, Moe Kadono, Shoso Munemasa, Takeshi Shimomura
Department of Hematology, National Hospital Organization Hiroshimanishi Medical Center
International Journal of Myeloma 11 (2) 92-92, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-12. Clinical significance of minimal residual disease in myeloma ; single center retrospective analysis
Kazuhito Suzuki1,2, Kaichi Nishiwaki1,2, Riku Nagao1,2, Mitsuji Katori1,2, Susumu Tanoue1,2, Daiki Hattori1,2, Hidekazu Masuoka1,2, Shingo Yano2
1Division of Clinical Oncology and Hematology, The Jikei University Kashiwa Hospital, 2Division of Clinical Oncology and Hematology, The Jikei University School of Medicine
International Journal of Myeloma 11 (2) 93-93, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.06MB)
P-13. Serial detection of MYD88 L265P mutation in BJP-MGUS patient with Fanconi syndrome
Nobuyuki Kodama1,2, Masataka Takeshita1,2, Tomoko Hishima1,2, Daisuke Kudo1, Kouji Okazaki1, Yuko Okuda1, Risen Hirai1, Akira Tanimura1, Akiyoshi Miwa1,2
1Department of Hematology, Tokyo-Kita Medical Center, 2International Myeloma Center for Advanced Research and Treatment
International Journal of Myeloma 11 (2) 94-94, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.05MB)
P-14. Urinary liver-type fatty acid binding protein (L-FABP) as a new biomarker of renal impairment in patients with multiple myeloma
Yosei Fujioka1, Kazuhiro Toyama1, Fumio Nakahara1, Mineo Kurokawa1,2
1Department of Hematology and Oncology, Graduate school of Medicine, The university of Tokyo, 2Department of Cell Therapy and Transplantation Medicine, Graduate School of Medicine, The university of Tokyo
International Journal of Myeloma 11 (2) 95-95, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.22MB)
P-15. Propensity-score matched analysis of the efficacy of maintenance or continuous therapy on multiple myeloma
Shuji Ozaki1, Hiroshi Handa2, Hiromi Koiso3, Takayuki Saitoh4, Kazutaka Sunami5, Tadao Ishida6, Kenshi Suzuki6, Tomoko Narita7, Shinsuke Iida7, Yuichi Nakamura8, Kazuhito Suzuki9, Noriko Nishimura10, Murakami Hirokazu11, Kazuyuki Shimizu12
1Department of Hematology, Tokushima Prefectural Central Hospital, 2Department of Hematology, Gunma University Graduate School of Medicine, 3Infection Control and Prevention Center, Gunma University Hospital, 4Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 5Department of Hematology, National Hospital Organization Okayama Medical Center, 6Department of Hematology, Japanese Red Cross Medical Center, 7Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 8Department of Hematology, Saitama Medical University Hospital, 9Department of Clinical Oncology/Hematology, The Jikei University Kashiwa Hospital, 10Division of Hematology Oncology, Cancer Institute Hospital of the Japanese Society for Cancer Research, 11Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, 12Department of Hematology/Oncology, Higashi Nagoya National Hospital
International Journal of Myeloma 11 (2) 96-96, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
P-16. The study of ER stress signaling pathways contributing to immunogenic cell death in multiple myeloma
Yuta Shimizu
Division of Clinical Physiology and therapeutics, Keio University, Faculty of Pharmacy
International Journal of Myeloma 11 (2) 97-97, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
P-17. Efficacy and safety of carfilzomib-containing therapy for relapsed / refractory myeloma : Kyoto Clinical Hematology Study Group prospective observation
Yuka Kawaji-Kanayama1, Tsutomu Kobayashi1, Ayako Muramatsu1, Hitoji Uchiyama2, Nana Sasaki3, Nobuhiko Uoshima3, Mitsushige Nakao4, Ryoichi Takahashi5, Kazuho Shimura6, Hiroto Kaneko6, Miki Kiyota7, Katsuya Wada7, Yoshiaki Chinen8, Koichi Hirakawa8, Shin-ichi Fuchida9, Chihiro Shimazaki9, Yuji Shimura1, Shigeo Horiike1, Masafumi Taniwaki6,10, Junya Kuroda1
1Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 2Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 3Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, 4Department of Internal Medicine, Otsu Municipal Hospital, 5Department of Hematology, Omihachiman Community Medical Center, 6Department of Hematology, Aiseikai Yamashina Hospital, 7Department of Hematology, Matsushita Memorial Hospital, 8Department of Hematology, Fukuchiyama City Hospital, 9Department of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center, 10Center for Molecular Diagnostic and Therapeutics, Kyoto Prefectural University of Medicine
International Journal of Myeloma 11 (2) 98-98, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
P-18. Predictive value of serum TGFb and serum IL-6 for hypertension by carfilzomib in patients with relapsed / refractory multiple myeloma
Ayako Muramatsu1, Tsutomu Kobayashi1, Yuka Kawaji-Kanayama1, Hitoji Uchiyama2, Uoshima Nobuhiko3, Nana Sasaki3, Mitsushige Nakao4, Ryoichi Takahashi5, Kazuho Shimura6, Hiroto Kaneko6, Katsuya Wada7, Miki Kiyota7, Koichi Hirakawa8, Yoshiaki Chinen8, Shinichi Fuchida9, Chihiro Shimazaki9, Yuji Shimura1, Shigeo Horiike1, Masafumi Taniwaki1,6,10, Junya Kuroda1
1Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine, 2Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 3Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, 4Department of Internal Medicine, Otsu Municipal Hospital, 5Department of Hematology, Omihachiman Community Medical Center, 6Department of Hematology, Aiseikai Yamashina Hospital, 7Department of Hematology, Matsushita Memorial Hospital, 8Department of Hematology, Fukuchiyama City Hospital, 9Department of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center, 10Center for Molecular Diagnostic and Therapeutics, Kyoto Prefectural University of Medicine
International Journal of Myeloma 11 (2) 99-99, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
P-19. Overexpression of reprogramming genes leads to acquisition of malignant phenotype in multiple myeloma
Ryotaro Koyama
Division of Clinical Physiology and therapeutics, Keio University, Faculty of Pharmacy
International Journal of Myeloma 11 (2) 100-100, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
P-20. Venetoclax enhances NK-cell-mediated ADCC with daratumumab in myeloma cells expressing BCL2
Ayano Nakamura1, Susumu Suzuki2,3, Masao Seto1, Souichi Takasugi1, Jo Kanasugi1, Ichiro Hanamura1, Ryuzo Ueda2, Akiyoshi Takami1
1Division of Hematology, Department on Internal Medicine, Aichi Medical University, 2Department of Tumor Immunology, Aichi Medical University, 3Research Creation Support Center, Aichi Medical University
International Journal of Myeloma 11 (2) 101-101, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.06MB)
P-21. The multicenter retrospective study of poor PBSC mobilization in patients with multiple myeloma
Yurie Nagai1, Naoya Mimura1,2, Nobuhiro Tsukada3, Nobuyuki Aotsuka4, Masaki Ri5, Yuna Katsuoka6, Toshio Wakayama7, Rikio Suzuki8, Yoriko Harazaki9, Morio Matsumoto10, Kyoya Kumagai11, Takaaki Miyake12, Shuji Ozaki13, Katsuhiro Shono14, Hiroaki Tanaka15, Arika Shimura16, Yoshiaki Kuroda17, Kazutaka Sunami18, Kazuhito Suzuki19, Takeshi Yamashita20, Kazuyuki Shimizu21, Hirokazu Murakami22, Masahiro Abe23, Chiaki Nakaseko24, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Division of Hematology, Japanese Red Cross Medical Center, 4Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, 5Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 6Department of Hematology, National Hospital Organization Sendai Medical Center, 7Department of Hematology and Oncology, Shimane Prefectural Central Hospital, 8Department of Hematology/Oncology, Tokai University School of Medicine, 9Department of Hematology, Miyagi cancer center, 10Department of Hematology, National Hospital Organization Shibukawa Medical Center, 11Division of Hematology-Oncology, Chiba Cancer Center, 12Department of Hematology and Oncology, Shimane University Hospital, 13Department of Hematology, Tokushima Prefectural Central Hospital, 14Department of Hematology, Chiba Aoba Municipal Hospital, 15Department of Hematology, Asahi General Hospital, 16Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 17Department of Hematology, National Hospital Organization, Hiroshima-Nishi Medical Center, 18Department of Hematology, National Hospital Organization Okayama Medical Center, 19Department Clinical Oncology and Hematology, the Jikei University Kashiwa Hospital, 20Department of Internal Medicine, Keiju Medical Center, 21Department of Hematology/Oncology, Higashi Nagoya National Hospital, 22Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, 23Department of Hematology, Endocrinology and Metabolism, Tokushima University, 24Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 11 (2) 102-102, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.06MB)
P-22. Real world treatment patterns and clinical outcomes in multiple myeloma patients from the MDV claims database in Japan
Hiroshi Handa1, Tadao Ishida2, Shuji Ozaki3, Asuka Mori4, Kenichi Kato5, Shinsuke Iida6
1Department of Hematology, Gunma University Graduate School of Medicine, 2Director of Department of Hematology, Japanese Red Cross Medical Center, 3Department of Hematology, Tokushima Prefectural Central Hospital, 4Integrated Market Access, Janssen Pharmaceutical K. K., 5Medical Affairs, Janssen Pharmaceutical K.K., 6Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 11 (2) 103-103, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
P-23. Daratumumab containing regimen for multiple myeloma patients ; a single center experience
Hiroyuki Takahashi1, Rika Sakai1, Jun Nukui1, Mayumi Tokunaga1, Taisei Suzuki1, Hideaki Nakajima2
1Department of Hematology and Medical Oncology, Kanagawa Cancer Center, 2Department of Hematology and Clinical Immunologym, Yokohama City University Graduate School of Medicine
International Journal of Myeloma 11 (2) 104-104, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-24. Retrospective analysis of maintenance therapy with ixazomib for patients with multiple myeloma undergoing autologous stem-cell transplantation
Nobuhiro Tsukada, Moe Nomura, Hirofumi Irita, Kota Sato, Mizuki Ogura, Yu Abe, Tadao Ishida, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 11 (2) 105-105, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
P-25. Usefulness of bortezomib and high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest
Sayaka Ohno1, Kiyohito Hayashi1, Ryo Shimizu1, Akihiro Ishii2, Hiroaki Tanaka1
1Department of Hematology, Asahi General Hospital, 2Department of Transfusion Medicine, Asahi General Hospital
International Journal of Myeloma 11 (2) 106-106, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-26. Effects of new agents on multiple myeloma recurrence after autoPBSCT
Mizuki Ogura, Tadao Ishida, Moe Nomura, Hirofumi Irita, Junichiro Nashimoto, Kota Sato, Yu Abe, Nobuhiro Tsukada, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 11 (2) 107-107, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
P-27. Clinical outcome of primary plasma cell leukemia in the novel agent era : a retrospective study of eight cases
Masuho Saburi1, Masanori Sakata1, Hiroyuki Takata1, Yasuhiko Miyazaki1, Hitohiro Sasaki2, Kazuhito Itani2, Miyuki Abe2, Kazuhiro Kohno2, Yasuhiro Soga3, Katsuya Kawano4, Toshiyuki Nakayama2, Eiichi Ohtsuka1
1Department of Hematology, Oita Prefectural Hospital, 2Department of Hematology, Oita Kouseiren Tsurumi Hospital, 3Department of Clinical Laboratory, Oita Kouseiren Tsurumi Hospital, 4Department of Clinical Laboratory Technology, Oita Prefectural Hospital
International Journal of Myeloma 11 (2) 108-108, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-28. TOURMALINE-MM4 : Ixazomib vs placebo maintenance in newly diagnosed multiple myeloma patients not undergoing autologous stem cell transplant
Shinsuke Iida1, Meletios A. Dimopoulos2, Ivan Spicka3, Hang Quach4, Albert Oriol5, Roman Hajek6, Mamta Garg7, Meral Beksac8, Sara Bringhen9, Eirini Katodritou10, Wee Joo Chng11, Maria-Victoria Mateos13, Xavier Leleu12, Gareth Morgan14, Alexander Vorog15, Richard Labotka15, Bingxia Wang15, Sagar Lonial16
1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 2Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 31st Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, 4Department of Haematology, University of Melbourne, St. Vincent's Hospital, 5Institut d'Investigacio contra la Leucemia Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, 6Department of Hematooncology, University Hospital Ostrava, University of Ostrava, 7Haematology, Leicester Royal Infirmary / University Hospitals of Leicester NHS Trust, 8Department of Hematology, Ankara University, 9Division of Hematology, University of Torino, AOU Citta della Salute e della Scienza di Torino, 10Department of Hematology, Theagenion Cancer Hospital, 11Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore, 12Pole Regional de Cancerologie, Department of Haematology, CHU La Miletrie-Poitiers, 13Hematology, Hospital Universitario de Salamanca, University Hospital of Salamanca, IBSAL, CIC, IBMCC (USAL-CSIC), 14Perlmutter Cancer Center, NY Langone Health, 15Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 16Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University
International Journal of Myeloma 11 (2) 109-109, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
P-29. DARATUMUMAB PLUS LENALIDOMIDE / DEXAMETHASONE (D-RD) IN PTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) : UPDATED ANALYSIS OF MAIA
Katja Weisel1, Shaji K. Kumar2, Thierry Facon3, Saad Z. Usmani4, Torben Plesner5, Robert Z. Orlowski6, Cyrille Touzeau7, Supratik Basu8, Nizar J. Bahlis9, Hartmut Goldschmidt10, Michael O'Dwyer10, Christopher P. Venner10, Cyrille Hulin10, Lionel Karlin10, Meir Preis10, Annemiek Broyl10, William Renwick10, Markus Hansson10, Maria Krevvata10, Jianping Wang10, Rian Van Rampelbergh10
1Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 2Department of Hematology, Mayo Clinic Rochester, 3University of Lille, CHU Lille, Service des Maladies du Sang, 4Levine Cancer Institute/Atrium Health, 5Vejle Hospital and University of Southern Denmark, 6Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 7Hematology, University Hospital Hotel-Dieu, 8Royal Wolverhampton Hospitals NHS Trust and University, 9Arnie Charbonneau Cancer Research Institute, University of Calgary, 10Other
International Journal of Myeloma 11 (2) 110-110, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(0.98MB)
P-30. LONG-TERM OUTCOMES AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) BY RESPONSE FOR BORTEZOMIB / MELPHALAN / PREDNISONE (VMP) ± DARATUMUMAB (DARA) IN ALCYONE
Hiroyuki Takamatsu1, Paula Rodriguez-Otero2, Mario Boccadoro3, Roman Hajek4, Tomoaki Fujisaki5, Jae Hoon Lee6, Joaquin Martinez-Lopez7, Paulo Lucio8, Zsolt Nagy9, Ganna Usenko10, Anna Marina Liberati10, Mihaela Lazaroiu10, Dariusz Woszczyk10, Joanna Romejko-Jarosinska10, Stefan Tobias Knop10, Astrid Pavlovsky10, Cecily Forsyth10, Takayuki Ishikawa10, Katharine Gries10, Huiling Pei10, Anupa Kudva10
1Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 2Clinica Universidad de Navarra, IDISNA, 3University of Torino, 4University Hospital Ostrava and Faculty of Medicine and Faculty of Science, University of Ostrava, 5Matsuyama Red Cross Hospital, 6Gachon University Gil Medical Center, 7Hospital 12 de Octubre, H12O-CNIO, Haematological Malignancies Clinical Research Unit, Universidad Complutense, CIBERONC, 8Champalimaud Centre for the Unknown, 9Semmelweis Egyetem, 10Other
International Journal of Myeloma 11 (2) 111-111, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(0.99MB)
P-31. Prognostic analysis of MM patients who discontinued treatment with CR status
Hideki Asaoku1, Mitsuhiro Itagaki1, Yuta Katayama1, Takeshi Okatani1, Ryota Imanaka1, Kohei Kyo1, Fumiaki Jinnouchi1, Takuya nunomura1, Gentaro Kawano1, Tsuyoshi Muta2, Shinya Katsutani3, Koji Iwato3
1Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, 2Department of Blood Transfusion , Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, 3Department of Clinical Laboratory, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
International Journal of Myeloma 11 (2) 112-112, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-32. The therapeutic effects in Relapsed and / or Refractory multiple myeloma patients treated with Daratumumab
Riku Nagao, Kazuhito Suzuki, Mitsuji Katori, Susumu Tanoue, Daiki Hattori, Hidekazu Masuoka, Kaichi Nishiwaki, Shingo Yano
Department of Oncology and Hematology, JIKEI University Hospital
International Journal of Myeloma 11 (2) 113-113, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.06MB)
P-33. Carfilzomib / dexamethasone therapy for relapsed and refractory multiple myeloma
Hiroko Ueda, Takashi Moriyama, Tatsunori Ishikawa, Takanori Yoshioka, Masanori Makita, Kazutaka Sunami
Department of Hematology, National Hospital Organization Okayama Medical Center
International Journal of Myeloma 11 (2) 114-114, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.24MB)
P-34. Daratumumab with bortezomib, or lenalidomide and dexamethasone was efficacy for relapse or refractory multiple myeloma in our hospital
Takanori Toyama
Miyazaki Prefectural Nobeoka Hospital
International Journal of Myeloma 11 (2) 115-115, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
P-35. Experience of using Daratumumab for relapse and refractory multiple myeloma in our hospital
Jun-nosuke Uchihara
Naha City Hospital
International Journal of Myeloma 11 (2) 116-116, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.21MB)
P-36. A 10-year survey of varicella-zoster virus reactivation in multiple myeloma patients treated with proteasome inhibitors in the novel agent era
Yasukata Ohashi1,2, Megumi Yatabe1, Daisuke Niijima1, Arina Imamura1, Yoshiyuki Nagayama1, Kentaro Otsuka1, Yutaka Yachi1, Hironori Ueno3, Takahiro Yano3, Koji Higai2, Akihiro Yokoyama3,4
1Department of Pharmacy, National Hospital Organization Tokyo Medical Center, 2Laboratory of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, 3Division of Hematology, National Hospital Organization Tokyo Medical Center, 4Division of Transfusion Medicine, National Hospital Organization Tokyo Medical Center
International Journal of Myeloma 11 (2) 117-117, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
P-37. A Case of Life-threatening but Reversible Carfilzomib-induced Pulmonary Toxicity
Toru Miyajima, Reiki Ogasawara, Emi Yokoyama, Koh Izumiyama, Akio Mori, Makoto Saito, Masanobu Morioka, Takeshi Kondo
Blood Disorders Center, Aiiku Hospital
International Journal of Myeloma 11 (2) 118-118, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.05MB)
P-38. Single cell RNA analysis successfully identifies plasma cell clones with specific features in POEMS syndrome
Naoya Mimura1,2, Yusuke Isshiki1, Motohiko Oshima3, Kensuke Kayamori1, Yurie Nagai1, Masahide Seki4, Yaeko Nakajima-Takagi3, Tomoya Muto1, Shokichi Tsukamoto1, Yusuke Takeda1, Chikako Ohwada1,5, Sonoko Misawa6, Jun-ichiro Ikeda7, Masashi Sanada8, Satoshi Kuwabara6, Yutaka Suzuki4, Emiko Sakaida1, Chiaki Nakaseko5, Atsushi Iwama3
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, 4Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 5Department of Hematology, International University of Health and Welfare, 6Department of Neurology, Chiba University Graduate School of Medicine, 7Department of Pathology, Chiba University Hospital, 8Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center
International Journal of Myeloma 11 (2) 119-119, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.07MB)
P-39. Clinical impact of the bone lesion in POEMS syndrome ; a single-center experience of 119 patients
Tatsuzo Mishina1, Chikako Ohwada1,4, Tomoki Suichi2, Nagisa Oshima1, Tomoya Muto1, Shokichi Tsukamoto1, Shio Mitsukawa1,3, Yusuke Takeda1, Naoya Mimura1,3, Tohru Iseki1,3, Chiaki Nakaseko4, Sonoko Misawa2, Satoshi Kuwabara2, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Neurology, Chiba University Graduate School of Medicine, 3Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 4Department of Hematology, International University of Health and Welfare
International Journal of Myeloma 11 (2) 120-120, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.05MB)
P-40. COVID-19 in patients with multiple myeloma : A single center experience
Yusuke Takagi, Takuya Kawaguchi, Shunsuke Kuno, Keiko Niimi, Hiroshi Kosugi
Department of Hematology, Ogaki Municipal Hospital
International Journal of Myeloma 11 (2) 121-121, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
P-41. A case of symptomatic multiple myeloma developing in a patient with immune thrombocytopenia
Shunsuke Kunou, Takuya Kawaguchi, Yusuke Takagi, Keiko Niimi, Hiroshi Kosugi
Department of Hematology, Ogaki Municipal Hospital
International Journal of Myeloma 11 (2) 122-122, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-42. A case of newly diagnosed t(11 ; 14) multiple myeloma with CD19-positive clone
Kazuki Kiyohara, Tsuyoshi Sato, Takahiro Maeta, Shinri Miyajima, Motoki Takano, Maki Nishiya, Norifumi Sugawara, Ryousei Sasaki, Yoshiaki Okano, Satsuki Kamihara, Shuugo Kowata, Tastuo Oyake, Shigeki Itou
Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine
International Journal of Myeloma 11 (2) 123-123, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.22MB)
P-43. Carfilzomib-induced thrombotic microangiopathy in a patient with refractory multiple myeloma
Satoshi Yamamoto, Yumika Saito, Ikumi Kasahara, Keisuke Yamaguchi
Demartment of Hematology, Sapporo City General Hospital
International Journal of Myeloma 11 (2) 124-124, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
P-44. A case of Daratumumab with VMP therapy achieved a rapid and deep response for transplant-ineligible multiple myeloma with multiple plasmacytomas
Tadahiro Gunji, Atsushi Katsube, Takeshi Saito, Hiroki Yokoyama, Ryoko Fukushima, Hiroto Ishii, Aya Nakano, Shoko Ishii, Mamiko Momoki, Yasutaka Mochizuki, Takaki Shimada, Shingo Yano
Division of Clinical Oncology and Hematology, The Jikei University School of Medicine
International Journal of Myeloma 11 (2) 125-125, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.04MB)
LS1-1. New treatment strategy for relapsed and refractory multiple myeloma - Understand IsaPd regimen based on basic and clinical -
Yusuke Furukawa
Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University
International Journal of Myeloma 11 (2) 128-128, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
LS1-2. New treatment strategy for relapsed and refractory multiple myeloma - Understand IsaPd regimen based on basic and clinical -
Tadao Ishida
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 11 (2) 129-129, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.06MB)
LS2. Mechanisms of T cell immune dysfunction and immunotherapeutic strategies in multiple myeloma
Hideto Tamura
Division of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center
International Journal of Myeloma 11 (2) 130-130, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
LS3. Evidence and practice with carfilzomib-containing strategy for relapsed / refractory myeloma
Junya Kuroda
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine
International Journal of Myeloma 11 (2) 131-131, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
LS4. The optimal first line and sequential treatment strategies in multiple myeloma with focus on immunomodulatory drugs
Hirokazu Tanaka
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
International Journal of Myeloma 11 (2) 132-132, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
MS1. Multiple myeloma treatment for Elderly / Frail in community medicine
Hitoshi Hanamoto
Kindai University Nara Hospital, Department of Hematology
International Journal of Myeloma 11 (2) 133-133, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
MS2. Tips of how to detect and assess systemic AL amyloidosis smartly for good clinical practice
Nagaaki Katoh
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
International Journal of Myeloma 11 (2) 134-134, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
SS1-1. Current status and issues of treatment for transplant-ineligible multiple myeloma
Kazuhito Suzuki
Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital
International Journal of Myeloma 11 (2) 135-135, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
SS1-2. Current status and issues of treatment for transplant-eligible multiple myeloma
Nobuhiro Tsukada
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 11 (2) 136-136, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
SS2-1. Significance of DLd therapy as initial treatment considering CD38 expression status
Akihiro Kitadate
Akita University Graduate School of Medicine and Faculty of Medicine, Department of Hematology, Nephrology and Rheumatology
International Journal of Myeloma 11 (2) 137-137, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.03MB)
SS2-2. New treatment strategy for patients with newly diagnosed multiple myeloma who are ineligible for ASCT 〜 How to use Daratumumab 〜
Tadao Ishida
Department of Hematology, Myeloma AL Amyloid Unit, Japanese Red Cross Medical Center
International Journal of Myeloma 11 (2) 138-138, 2021.
  • 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
download全文ダウンロード(1.02MB)
はじめての方へ
個人／法人会員登録のご案内